Navigation Links
Rituximab and fludarabine produce long-term remissions in CLL
Date:2/25/2011

COLUMBUS, Ohio New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.

The multi-institutional study, led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, reports on the outcomes of 104 people with chronic lymphocytic leukemia (CLL) who were treated with the targeted agent rituximab and the chemotherapeutic drug fludarabine.

After nearly 10 years of follow-up, 13 percent of patients had remissions lasting more than seven years, and patients with certain genetic features in their CLL cells achieved long-term remission even when a small amount of disease remained after initial therapy.

"Our study shows that remissions of more than 10 years can be attained by combining fludarabine and rituximab in CLL without risk of secondary leukemia," says principal investigator Dr. John Byrd, director of the division of hematology, D. Warren Brown Chair of Leukemia Research and professor of medicine, of medicinal chemistry and of veterinary biosciences.

"We also identified prognostic factors at the time of diagnosis that predict long-term survival, which should allow us to predict which patients will most benefit from this regimen," he adds.

All patients were treated through a national clinical trial sponsored by the Cancer and Leukemia Group B (CALGB), a clinical cooperative group. The findings were reported online in the Journal of Clinical Oncology.

First author Dr. Jennifer Woyach, a hematology researcher at the OSUCCC James, notes that the findings are important because fludarabine plus rituximab and fludarabine plus cyclophosphamide and rituximab are the two most common regimens used to treat CLL.

"We learned from this study that many patients with low-risk disease will have excellent outcomes with the two-drug combination, so they can be spared the toxicity that comes with the addition of cyclophosphamide. In addition, we show that it is possible to achieve long-term remission without completely eliminating the disease, which challenges the existing belief that it is necessary to completely eradicate the disease for long-term remission in low-risk patients.

"Importantly, we show that, unlike the three-drug combination, fludarabine plus rituximab does not increase the risk of therapy-related acute leukemias in CLL patients," she says. "This is important because these malignancies are difficult to treat and have an extremely poor prognosis."


'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Study Adds to Evidence That Rituximab Slows Lymphoma Symptoms
2. Insects that deter predators produce fewer offspring
3. Sperm-Producing Cells Coaxed to Produce Insulin
4. Chronic high cholesterol diet produces brain damage
5. Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health
6. Gene therapy for metastatic melanoma in mice produces complete remission
7. Detroits urban farms could provide a majority of produce for local residents
8. MIT chemists engineer plants to produce new drugs
9. War on cancer produces collateral damage to the heart
10. Eggs Being Produced by Recall Farms Safe, if Pasteurized, Experts Say
11. Surgeon-engineer team produce training software for robot-assisted surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for ... so many other applications. Users can pick and choose from hand-crafted trend-setting ...
(Date:2/17/2017)... ... 17, 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, ... and non-controlled substances plus the ability to manage orders on their desktop or ... accept electronic prescriptions, according to the Office of the National Coordinator of Health ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... ... 17, 2017 , ... PrideStaff, a national staffing organization, is ... Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , Now in ... to the staffing industry over the last twelve months. Industry insiders and observers ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... planning assistance to families and business owners in the greater Fort Lauderdale metropolitan ... organization. , For more than 30 years, LifeNet 4 Families has provided ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Research and Markets has announced the ... Technologies" report to their offering. ... Traditional medical devices include ... non-drug coated implantables, large endoscopes, needle based drug delivery, lab ... last two to three decades for the treatment and management ...
(Date:2/16/2017)... 2017 DaVita Inc. (NYSE: DVA ) ... 31, 2016. Net income attributable to DaVita ... was $158 million, or $0.80 per share and $880 million, ... income attributable to DaVita Inc. for the quarter and year ... was $192 million, or $0.98 per share, and $789 million, ...
(Date:2/16/2017)... , Feb. 16, 2017  Aralez Pharmaceuticals Inc. ... specialty pharmaceutical company, today announced that executive management will ... to be held February 22-23, 2017. Adrian Adams ... the Company at 1:35 p.m. local time on Wednesday, ... audio archive for the event may be accessed from ...
Breaking Medicine Technology: